Satellite Symposia

Overview

Several industry-sponsored satellite symposia are featured alongside the main program. These sessions highlight emerging data from pharmaceutical sponsors and provide practical clinical perspectives.

Day 1 Satellite Symposium

AstraZeneca — Unravelling Novel Treatment in ASCT-Ineligible MCL

Time: 1:05–1:50 p.m.

Key Focus Areas:

  • Mantle cell lymphoma (MCL) in patients ineligible for autologous stem cell transplant (ASCT)
  • BTK inhibitor–based approaches and novel combinations
  • Acalabrutinib and other next-generation BTK inhibitors in frontline MCL
  • Treatment sequencing considerations for elderly/unfit MCL patients
What to Watch For

The evolving role of covalent vs. non-covalent BTK inhibitors in MCL, and emerging data on fixed-duration combination regimens for transplant-ineligible patients.

Day 2 Satellite Symposia

Johnson & Johnson — Bridging Early and Late Lines in Multiple Myeloma

Time: 7:45–8:30 a.m.

Key Focus Areas:

  • Clinical evidence shaping frontline and relapsed/refractory myeloma care
  • Anti-CD38 monoclonal antibody–based quadruplet regimens
  • Bispecific antibody platforms (teclistamab, talquetamab)
  • Treatment sequencing from frontline through late relapse

Kyan Technologies — Selecting the Right Treatment in NHL: From Genomics to Functional Precision Medicine

Time: 7:45–8:30 a.m.

Key Focus Areas:

  • Genomic profiling for NHL treatment selection
  • Functional precision medicine approaches (ex vivo drug sensitivity testing)
  • Integration of molecular and functional data for personalized therapy
  • Real-world applications in treatment-naive and relapsed NHL

Novartis — Paving the Way for CML Management

Time: 12:35–1:20 p.m.

Key Focus Areas:

  • Chronic myeloid leukemia (CML) frontline management
  • Asciminib (STAMP inhibitor) and its role in treatment optimization
  • Treatment-free remission (TFR) strategies
  • Switching strategies for intolerance or suboptimal response

PharmaEssentia — A Paradigm Shift in Management of MPN

Time: 12:35–1:20 p.m.

Key Focus Areas:

  • Ropeginterferon alfa-2b in polycythemia vera (PV) and myelofibrosis
  • Disease modification potential with interferons
  • Long-term molecular response data
  • Early intervention strategies in MPN

Roche — Defining a New Standard of Care in R/R DLBCL with STARGLO

Time: 12:35–1:20 p.m.

Key Focus Areas:

  • STARGLO trial 3-year updated results
  • Glofitamab + gemcitabine/oxaliplatin in relapsed/refractory DLBCL
  • Clinical insights and real-world case discussions
  • Bispecific antibody sequencing and safety management